CAH

Cardinal Health Inc. 10-Q Summary: Quarter Ended December 31, 2000

Business Context and Reporting Period

This Form 10-Q covers the three and six months ended December 31, 2000, for Cardinal Health, Inc., a diversified healthcare services company. The Company operates through four segments: Pharmaceutical Distribution and Provider Services, Medical-Surgical Products and Services, Pharmaceutical Technologies and Services, and Automation and Information Services. The reporting period includes the impact of recent acquisitions, including Bergen Brunswig Medical Corporation (BBMC), and ongoing integration of prior mergers (ALP, Allegiance, Scherer).

Key Financial Metrics

Margin Analysis: Consolidated gross margin as a percentage of operating revenue decreased to 10.44% for the quarter and 10.49% for the six-month period, compared to 11.54% and 11.39% in the prior year, respectively. This decline is attributed to a higher mix of lower-margin pharmaceutical distribution sales.

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 30% year-over-year for the quarter and 29% for the six-month period. Operating revenue grew 24% and 22%, respectively. Growth was driven by increased volume, price increases, and acquisitions (notably BBMC).
• Profitability: Net earnings rose 21% for the quarter and 29% for the six-month period compared to the prior year. Operating earnings increased 18% and 23%, respectively.
• Merger Costs: Merger-related costs were $7.0 million for the quarter and $24.3 million for the six months, a decrease from $5.5 million and $42.3 million in the prior year periods. This reduction was partly due to a $10.3 million credit adjusting prior estimates for the Allegiance merger.
• Liquidity: Working capital increased from $2.6 billion to $3.4 billion. Cash and equivalents decreased by $88.4 million over the six months due to operating cash outflows and investing activities, partially offset by financing activities.

Guidance, Outlook, and Risks

• Future Merger Costs: Management estimates approximately $65.7 million ($42.7 million net of tax) in additional merger-related and integration costs will be incurred in future periods, primarily fiscal 2001 and 2002.
• Bindley Merger: The Company announced a definitive stock-for-stock merger with Bindley Western Industries, Inc., expected to close on February 14, 2001. The transaction will be accounted for as a pooling-of-interests.
• Legal Contingencies: The Company faces approximately 571 lawsuits regarding natural rubber latex glove sensitization assumed from the Allegiance acquisition. While the Company believes a substantial portion of liability will be covered by insurance, it cannot currently estimate the potential loss.
• Capital Resources: The Company increased its commercial paper capacity to $1.5 billion and maintains a $1.5 billion unsecured bank credit facility. It also issued $400 million in preferred debt securities via a special purpose entity (SPE).

Investor Verification Checklist

• Merger Integration Costs: Verify the timing and magnitude of the estimated $65.7 million in future merger-related expenses.
• Latex Litigation Exposure: Monitor developments in the 571 pending latex glove lawsuits and the status of insurance arbitration with AEIA.
• Bindley Merger Closing: Confirm the successful consummation of the Bindley merger and its impact on future financial reporting (pooling-of-interests).
• Margin Trends: Assess whether the decline in gross margin percentage stabilizes as the product mix adjusts post-acquisition.
• Debt Structure: Review the terms of the $400 million SPE preferred debt and the $500 million 6.75% Notes issued in February 2001.